Victory Capital Management
SAGE

Victory Capital Management’s Sage Therapeutics SAGE Stock Holding History

Victory Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-42,161
Closed -$1.98M – 2550
2023
Q2 		$1.98M Buy
42,161
+17,733
+73% +$882K ﹤0.01% 1392
2023
Q1 		$1.02M Buy
24,428
+9,379
+62% +$403K ﹤0.01% 1677
2022
Q4 		$574K Sell
15,049
-12,583
-46% -$481K ﹤0.01% 1961
2022
Q3 		$1.08M Buy
27,632
+21,407
+344% +$827K ﹤0.01% 1700
2022
Q2 		$201K Buy
+6,225
New +$209K ﹤0.01% 2354
2022
Q1 		– Sell
-10,928
Closed -$465K – 2799
2021
Q4 		$465K Buy
10,928
+1,683
+18% +$70.5K ﹤0.01% 2186
2021
Q3 		$410K Buy
9,245
+2,426
+36% +$111K ﹤0.01% 2275
2021
Q2 		$387K Sell
6,819
-682,185
-99% -$48.2M ﹤0.01% 2323
2021
Q1 		$51.6M Sell
689,004
-44,893
-6% -$3.68M 0.05% 536
2020
Q4 		$63.5M Sell
733,897
-342,840
-32% -$25.3M 0.07% 427
2020
Q3 		$65.8M Buy
1,076,737
+95,631
+10% +$4.85M 0.08% 341
2020
Q2 		$40.8M Sell
981,106
-1,211,610
-55% -$44M 0.06% 498
2020
Q1 		$63M Buy
2,192,716
+1,418,129
+183% +$82.1M 0.05% 496
2019
Q4 		$55.9M Buy
774,587
+191,729
+33% +$23.6M 0.07% 429
2019
Q3 		$81.8M Buy
582,858
+105,967
+22% +$17.7M 0.11% 273
2019
Q2 		$87.3M Buy
476,891
+42,670
+10% +$7.28M 0.18% 147
2019
Q1 		$69.1M Sell
434,221
-29,320
-6% -$4.25M 0.16% 176
2018
Q4 		$44.4M Buy
463,541
+42,806
+10% +$4.9M 0.11% 279
2018
Q3 		$59.4M Sell
420,735
-54,930
-12% -$8.48M 0.12% 258
2018
Q2 		$74.5M Buy
475,665
+40,850
+9% +$6.41M 0.16% 167
2018
Q1 		$70M Buy
434,815
+152,885
+54% +$26M 0.15% 189
2017
Q4 		$46.4M Sell
281,930
-49,475
-15% -$4.8M 0.1% 327
2017
Q3 		$20.6M Sell
331,405
-114,080
-26% -$8.96M 0.05% 575
2017
Q2 		$35.5M Sell
445,485
-44,930
-9% -$3.25M 0.08% 397
2017
Q1 		$34.9M Buy
490,415
+16,577
+3% +$971K 0.08% 413
2016
Q4 		$24.2M Sell
473,838
-27,720
-6% -$1.31M 0.06% 517
2016
Q3 		$23.1M Buy
+501,558
New +$20.4M 0.06% 515

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management's SAGE Position: Q3 2023 in Review

Victory Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 42,161 shares — an estimated $1.98M sold.

Victory Capital Management first reported a position in SAGE in Q3 2016 and held it in 27 quarters. The position peaked at $87.3M in Q2 2019. 193 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Victory Capital Management reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Victory Capital Management sold 42,161 Sage Therapeutics shares in Q3 2023, an estimated $1.98M.
  • Victory Capital Management first reported a position in Sage Therapeutics in Q3 2016 and held it in 27 quarters.
  • Victory Capital Management's Sage Therapeutics position peaked at $87.3M in Q2 2019.
  • 193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Victory Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.